Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Barry

Showing results (161-170 of 166) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 166 results.
Structure (London, England : 1993)|January 31, 2017
Allosteric Mutant IDH1 Inhibitors Reveal Mechanisms for IDH1 Mutant and Isoform SelectivityXiaoling Xie, Daniel Baird, Kimberly Bowen, et al.
Journal of Medicinal Chemistry|May 18, 2016
Toward the Validation of Maternal Embryonic Leucine Zipper Kinase: Discovery, Optimization of Highly Potent and Selective Inhibitors, and Preliminary Biology InsightB Barry Touré, John Giraldes, Troy Smith, et al.
ACS Medicinal Chemistry Letters|February 16, 2017
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1Julian R Levell, Thomas Caferro, Gregg Chenail, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 1, 2024
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2Heike Schönherr, Pelin Ayaz, Alexander M Taylor, et al.
Journal of Medicinal Chemistry|July 13, 2013
Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitorMichael D Shultz, Atwood K Cheung, Christina A Kirby, et al.
Cancer Discovery|June 4, 2023
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance MutationsVivek Subbiah, Vaibhav Sahai, Dejan Maglic, et al.
Pageof 17

Showing results (161-170 of 166) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 166 results.
Structure (London, England : 1993)|January 31, 2017
Allosteric Mutant IDH1 Inhibitors Reveal Mechanisms for IDH1 Mutant and Isoform SelectivityXiaoling Xie, Daniel Baird, Kimberly Bowen, et al.
Journal of Medicinal Chemistry|May 18, 2016
Toward the Validation of Maternal Embryonic Leucine Zipper Kinase: Discovery, Optimization of Highly Potent and Selective Inhibitors, and Preliminary Biology InsightB Barry Touré, John Giraldes, Troy Smith, et al.
ACS Medicinal Chemistry Letters|February 16, 2017
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1Julian R Levell, Thomas Caferro, Gregg Chenail, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 1, 2024
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2Heike Schönherr, Pelin Ayaz, Alexander M Taylor, et al.
Journal of Medicinal Chemistry|July 13, 2013
Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitorMichael D Shultz, Atwood K Cheung, Christina A Kirby, et al.
Cancer Discovery|June 4, 2023
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance MutationsVivek Subbiah, Vaibhav Sahai, Dejan Maglic, et al.
Pageof 17